ArticleAnnals of the American Thoracic Society2026
Risk factors for longitudinal estimated glomerular filtration rate decline in adults with cystic fibrosis.
Article in Annals of the American Thoracic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
rationaleIn contemporary cohorts of adults with cystic fibrosis (CF), risk factors and rates of kidney function decline are unknown. With improved life expectancy, preserving kidney function is paramount to preventing early cardiovascular disease and CF-related bone disease and to maintaining eligibility for lung transplantation.
objectivesTo determine long-term kidney function decline among CF participants following the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2) clinical trial and to identify specific risk factors.
methodsWe linked participants in STOP2 with the CF Foundation Patient Registry and defined decline in kidney function as a composite of ≥40% decline in the estimated glomerular filtration rate (eGFR) or development of end-stage renal disease. We calculated the associations of risk factors such as age, diabetes status, and number of pulmonary exacerbations treated with intravenous antibiotics on decline in kidney function.
resultsAmong 915 STOP2 participants, the mean ± SD baseline eGFR was 114 ± 20 mL/min/1.73 m2 and 53 (6.0%) reached the composite endpoint over a median follow-up time of 3.8 years. Each 10-year increase in age was associated with a 24% greater risk of the composite outcome (hazard ratio [HR], 1.29 [95% CI, 1.01-1.65]), and participants with insulin-dependent diabetes had a greater risk of the composite endpoint (HR, 2.34 [95% CI, 1.33-4.12]). A multivariable adjusted time-updated Cox regression model demonstrated that each additional pulmonary exacerbation was associated with a greater risk of the composite outcome (HR, 1.13 [95% CI, 1.07-1.20]; P <.0001).
conclusionsRisk factors associated with kidney function decline included age, insulin-dependent diabetes, and number of pulmonary exacerbations. These findings highlight key contributors to kidney function decline in a modern cohort of adults with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.